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Abstract
Carbon monoxide-releasing molecules (CORMs) are a promising class of new antimicrobials, with multiple modes of action
that are distinct from those of standard antibiotics. The relentless increase in antimicrobial resistance, exacerbated by a lack
of new antibiotics, necessitates a better understanding of how such novel agents act and might be used synergistically with
established antibiotics. This work aimed to understand the mechanism(s) underlying synergy between a manganese-based
photoactivated carbon monoxide-releasing molecule (PhotoCORM), [Mn(CO)3(tpa-k
3N)]Br [tpa=tris(2-pyridylmethyl)amine], and
various classes of antibiotics in their activities towards Escherichia coli EC958, a multi-drug-resistant uropathogen. The title
compound acts synergistically with polymyxins [polymyxin B and colistin (polymyxin E)] by damaging the bacterial
cytoplasmic membrane. [Mn(CO)3(tpa-k
3N)]Br also potentiates the action of doxycycline, resulting in reduced expression of
tetA, which encodes a tetracycline efflux pump. We show that, like tetracyclines, the breakdown products of [Mn(CO)3(tpa-k
3
N)]Br activation chelate iron and trigger an iron starvation response, which we propose to be a further basis for the
synergies observed. Conversely, media supplemented with excess iron abrogated the inhibition of growth by doxycycline and
the title compound. In conclusion, multiple factors contribute to the ability of this PhotoCORM to increase the efficacy of
antibiotics in the polymyxin and tetracycline families. We propose that light-activated carbon monoxide release is not the
sole basis of the antimicrobial activities of [Mn(CO)3(tpa-k
3N)]Br.
INTRODUCTION
Carbon monoxide-releasing molecules (CORMs) were
originally developed to deliver carbon monoxide (CO) safely
in experimental and therapeutic settings [1], in recognition
of mounting evidence that CO is an important signalling
molecule [2] with opportunities for therapeutic exploitation
[3]. A wide range of CORMs has now been developed and
diverse modifications have been employed to control and
manipulate the CO release triggers and kinetics [4–7].
It is axiomatic that CO is a competitive inhibitor of O2 bind-
ing to ferrous haem proteins, especially respiratory terminal
oxidases and globins. At high ratios of CO :O2 (typically
~9 : 1), CO inhibits aerobic respiration [8]. It was therefore
predicted that CORMs might possess antimicrobial activity
and that these actions would be primarily due to respiratory
inhibition [9, 10]. Although CORM-2 and CORM-3 do
inhibit aerobic respiration of E. coli [10–12], P. aeruginosa
[13, 14] and other bacteria, mounting evidence is highlight-
ing the multifaceted effects of CORMs, which cannot solely
be due to CO [15, 16]. Firstly, CORM-2 and CORM-3 are
more potent inhibitors of growth and/or aerobic respiration
than CO gas itself, implying that Ru(II) or some other
decomposition products of the CORM enhance inhibition
[10, 14]. Secondly, transcriptomic studies revealed diverse
changes in gene expression, not limited to respiratory
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function, especially involving membrane stress and drug
efflux systems in response to CORM-2 and CORM-3 but not
CO gas [10, 17, 18]. Thirdly, despite the fact that the classical
targets of CO are ferrous haem proteins, CORM-3 is toxic to
haem-deficient E. coli mutants and the naturally haem-defi-
cient Gram-positive bacterium Lactococcus lactis [19].
The antimicrobial potency of CORMs is poorly understood,
a problem confounded by the potential toxicity of the ruthe-
nium (Ru) in the most commonly used CORMs [18, 19];
this led us to explore a manganese (Mn)-based photoacti-
vated carbon monoxide-releasing molecule (PhotoCORM)
[Mn(CO)3(tpa-k
3N)]Br [20]. The term PhotoCORM [21]
describes a compound that releases CO when it is exposed
to light [22]. Such compounds have the advantage that CO
release can be precisely controlled, and comparisons of the
biological effects of the pro-drug versus the CO-depleted or
photo-activated compound allow us to discern the role of
CO and that of the metal-coligand fragment. Moreover,
many advances have been made recently in the field of pho-
toactivated chemotherapy (PACT) [23], including in the
treatment of cancer [24], thus providing the technology
required to make the therapeutic use of PhotoCORMs a
possibility. [Mn(CO)3(tpa-k
3N)]Br, upon photoactivation,
inhibits the growth and reduces the viability of E. coli K-12
[20] and the uropathogenic E. coli (UPEC) EC958 [25]. The
mechanism of toxicity of this compound is not fully under-
stood, but CO released from the PhotoCORM binds to
respiratory cytochromes and inhibits respiration, while
metal ion acquisition is perturbed.
This work focuses on E. coli EC958, a clinical isolate of E.
coli ST131 [26]. The multidrug-resistant UPEC clone
belonging to serotype O25b:H4 and sequence type E. coli
ST131 has emerged as a major cause of urinary tract and
bloodstream infections, and a worldwide public health
threat [27]. E. coli ST131 produces cefotaxime (CTX)-M-
type extended spectrum b-lactamases (ESBLs) [28] and
exhibits resistance to b-lactams and several classes of non-
b-lactams (e.g. fluoroquinolones), significantly limiting
treatment options [29, 30]. The increasing prevalence of
ST131 strains requires novel antimicrobial strategies to
combat infections.
One approach to combat antibiotic resistance is the use of
combinatorial therapies with the aim of reducing depen-
dence on single antibiotics [31]. Previously, we showed that
the title compound potentiates the effects of the antibiotic,
doxycycline (DOX), which binds to the 30S subunit of the
bacterial ribosome, preventing protein synthesis [25]. Here
we set out to investigate whether [Mn(CO)3(tpa-k
3N)]Br is
synergistic with other antibiotics against strain EC958, spe-
cifically those that: inhibit protein synthesis at the 30S sub-
unit of the bacterial ribosome [gentamycin (GEN),
kanamycin (KAN) and tetracycline (TET)]; bind to the 50S
subunit [chloramphenicol (CHL)]; interact with penicillin-
binding proteins, thus inhibiting cell wall biosynthesis [cefo-
taxime (CTX)]; inhibit dihydrofolate reductase activity and
DNA synthesis [trimethoprim (TMP)]; or bind to and
disrupt the outer membrane [colistin (CST) and polymyxin
B (PMB)]. We investigate the basis of the synergy and show
that iron starvation and membrane damage are key to
understanding the mechanism of toxicity of the Photo-
CORM, both alone and in the presence of antibiotics.
METHODS
PhotoCORM preparation and use
The synthesis of [Mn(CO)3(tpa-k
3N)]Br was described pre-
viously [20]. Aqueous stock solutions (10mM) were kept in
the dark for up to 24 h at 4

C. The PhotoCORM was acti-
vated by adding PhotoCORM to cells and immediately illu-
minating the culture for 6min at 365 nm with a UV lamp
(UVITEC, Cambridge) placed 3 cm above the sample. CO-
depleted PhotoCORM was prepared by exposing 1ml of
PhotoCORM (3mM) to UV light at 365 nm for 30min with
stirring.
Determination of minimum inhibitory
concentrations (MICs) using E-tests
E-tests were performed in accordance with the manufac-
turer’s instructions (bioMerieux SA). Briefly, inocula of E.
coli EC958 and MG1655 were prepared and adjusted to 0.5
McFarland standard and spread onto Mueller–Hinton II
agar plates. The MIC breakpoints for defining interpretive
categories published by EUCAST [32] were used for inter-
preting E-test MIC values.
Growth conditions
Starter cultures of EC958 were grown in LB (Luria-Bertani)
broth overnight at 37

C, 200 r.p.m. After centrifugation,
cells were suspended in minimal medium [33] or Fe-supple-
mented minimal medium [in which the basal FeCl3 concen-
tration (31 µM) was increased by 10- or 50-fold] with
glucose (20mM) as the sole carbon source. This suspension
was used to inoculate fresh medium [106 colony-forming
units (c.f.u.) ml 1] in 96-well plates and the cultures were
treated with [Mn(CO)3(tpa-k
3N)]Br and/or various antibi-
otics (polymyxins, tetracyclines and aminoglycosides) as
described in the Results section. For studies with iron chela-
tors, cultures were treated with citric acid, desferrioxamine
or 8-hydroxyquinoline in the presence or absence of the
PhotoCORM. To activate the PhotoCORM, 96-well plates
with 200 µl culture volumes were exposed to UV as above.
Plates were incubated overnight at 37

C, 200 rpm, in a Sun-
rise microplate reader (TECAN).
Checkerboard experiments
Experiments were performed in 96-well plates as described
before [31, 34]. Cultures were incubated at 37

C with shak-
ing for 24 h using a Tecan Sunrise plate reader [See Fig.
S1 (available in the online Supplementary Material) for
more information]. The concentrations of antibiotics
(Sigma) tested were up to four eightfold dilutions lower
than the MIC and, where possible, two twofold dilutions
higher than the MIC. The MIC was considered as the lowest
concentration of the agent alone, or combined with CORM-
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401, that inhibited growth. The fractional inhibitory con-
centration index (FICI) [31] was calculated to determine
drug interaction, and interpreted as follows: FICI of two-
drug combination=FICA+FICB, where FICA is the MIC of
drug A in combination with CORM-401/MIC of drug A
alone and FICB is the MIC of drug B in combination with
CORM-401/MIC of drug B alone. The results indicate syn-
ergy when the calculated FICI 0.5, no interaction when
FICI >0.5–4 and antagonism when the FICI >4 [35].
Metal uptake analyses
Aerobic cultures of EC958 were grown to mid-exponential
phase (OD600~0.4). To measure intracellular Mn, cultures
were treated with either 50 µM or 150 µM activated Photo-
CORM alone or in combination with the following anti-
biotics: CST (0.5 µgml 1); DOX (12.5 µgml 1); OTC
(12.5 µgml 1). These lower concentrations of PhotoCORM
were used in an effort to minimize metabolic inhibition,
since we were interested in determining whether the CORM,
assayed as Mn, was actively transported, whereas to measure
intracellular Fe, cultures were treated with 300 µM activated
PhotoCORM to test for iron depletion from the medium by
the PhotoCORM. Cultures were incubated for 40min before
samples were taken and analysed by inductively coupled
plasma mass spectrometry (ICP-MS) as previously described
[10] using values from the literature for single-cell dry mass
and volume [36]. Intracellular metal ion concentrations were
determined for cell pellets; extracellular concentrations were
determined for supernatant and wash fractions.
Liposome leakage assay
Liposomes were prepared as described previously [37].
Briefly, liposomes consisting of only (1,2-dioleoyl-sn-glyc-
ero-3-phospho-1¢-rac-glycerol) (sodium salt) (DOPG)
(Avanti Polar Lipids) or DOPG in combination with 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) in the
ratio DOPE:DOPG (7 : 3mol parts) and containing 50mM
5(6)-carboxyfluorescein (Thermo Fisher) were prepared by
extrusion through 0.2 µm polycarbonate filters (Merck
Millipore). Excess dye was removed by filtration through a
Sephadex G-25 column using 10mM HEPES pH 7.4 as the
eluting buffer. To measure the rate of 5(6)-carboxyfluores-
cein leakage, the liposomes were diluted (1/6000) in 10mM
HEPES buffer, pH 7.4. The fluorescence emission at 517 nm
(excitation at 495 nm) was monitored with a Varian Cary
Eclipse fluorescence spectrophotometer (Agilent Technolo-
gies) prior to and following the addition of the PhotoCORM
(50 µM). The sample was then exposed to UV (365 nm,
6min) and fluorescence monitoring was resumed. The
membrane-disrupting antibiotic CST (30 µM) was used as a
positive control and total leakage was determined by the
addition of Triton X-100 (0.01%) (Sigma).
Inner-membrane depolarization assay
The cytoplasmic membrane depolarization activity of the
PhotoCORM in respect of E. coli EC958 was determined as
described before [38]. In the present study, CST (3 µM) was
used as a positive control to determine the total cytoplasmic
membrane depolarization as measured using the membrane
potential-sensitive fluorescent dye 3,3¢-dipropylthiadicarbo-
cyanine iodide [diSC3(5)].
RT-PCR
Exponential-phase cultures were treated with the Photo-
CORM (150 µM) alone or in combination with DOX (9 µg
ml 1), or CST (1 µgml 1). Following treatment, cultures
containing the PhotoCORM were exposed to UV (365 nm,
6min) and then incubated at 37

C for 10min with shaking
at 200 r.p.m. RT-PCR experiments were performed as
before [25]. The primer sets used were: katG, 5¢ CCATAA-
CACCACAGCCACTG 3¢ and 5¢ AGTTGATTTGGCCAC-
CAGTC 3¢; sodA, 5¢ TGAGCTATACCCTGCCATCC 3¢
and 5¢ TCTGATGGTGTTTGGTGTGG 3¢; ahpC, 5¢ GAAA
TCACCGAAAAAGATACCG 3¢ and 5¢ CAGTTCTTCGT
AATGGTCAGCA 3¢; recA, 5¢ TCTACCGGTTCGCTTT
CACT 3¢ and 5¢ CGTGGTTTTACCGGAAGATT 3¢; tetA,
5¢ CAGACGTGAAACCCAACAGAC 3¢ and 5¢ ACGTCG
TTCGAGTGAACCAG 3¢; and gyrA, 5¢ GGTACACCG
TCGCGTACTTT 3¢ and 5¢ TACCGATTACGTCACCA
ACG 3¢.
Iron chelation assay
Chrome Azurol S (CAS) assay solution was prepared as
before [39]. Samples of the PhotoCORM (300 µM or
1.5mM), the CO-depleted PhotoCORM (300 µM), DOX (9
or 96 µgml 1), tris(2-pyridylmethyl)amine (tpa), manga-
nese(II) perchlorate (Mn(ClO4)2), or CO gas (gently bub-
bled through the sample for 5min) were added alone or in
combination to either Tris-HCl buffer (50mM, pH 7.4) or a
suspension of EC958 cells. Samples were kept in the dark or
illuminated at 365 nm for 6min. Samples containing bacter-
ia (OD600~0.8) were then centrifuged (5000 r.p.m.) and
500 µl supernatant was incubated at room temperature for
1 h with 500 µl CAS assay solution. A UV visible spectrum
was then recorded (300–800 nm) and the absorbance at
630 nm was noted for each sample.
RESULTS
Light-activated [Mn(CO)3(tpa-k
3N)]Br potentiates the
inhibitory effects of antibiotics
E. coli strain EC958 was subjected to E-test strips (Epsilome-
ter tests; bioMerieux) – pre-defined, stable gradients of 15
antimicrobial concentrations on a plastic strip, routinely
used to assess antibiotic sensitivity. In contrast to laboratory
E. coli strain MG1655, EC958 was resistant to multiple clas-
ses of antibiotics, including tetracyclines (DOX and TET),
an aminoglycoside (KAN) and a dihydrofolate reductase
inhibitor (TMP) (Table S1). These findings are predicted by
the genome sequence, which shows that plasmid pEC958
includes genes for antibiotic resistance, including tetA and
tetR (encoding tetracycline resistance proteins), aac6¢-lb-cr
[encoding aminoglycoside N(6’)-acetyltransferase] and
dhfrVII (encoding dihydrofolate reductase [26]).
To investigate whether [Mn(CO)3(tpa-k
3N)]Br enhances
the inhibitory effects of antibiotics, EC958 cultures were
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treated with increasing concentrations of antibiotics in the
absence or presence of a concentration of the activated
PhotoCORM (200 µM) that elicited partial inhibition of
growth [25]; cells were treated with the compound and illu-
minated in situ at 365 nm to allow for CO release (Fig. 1).
Activated PhotoCORM reduced the MICs of certain antibi-
otics, including DOX (reduced from 96 to 24 µgml 1), CST
(8 to 1 µgml 1), KAN (96 to 48 µgml 1) and GEN (6.4 to
1.6 µgml 1), whereas the MICs for CTX and CHL were
unaltered (not shown). UV-activated [Mn(CO)3(tpa-k
3N)]
Br (200 µM) also potentiated the growth inhibitory effects
of GEN, DOX and CST (Fig. 2a–c, right-hand panels). The
effect was most marked with DOX (Fig. 2b) and especially
CST (Fig. 2c). However, CO-depleted PhotoCORM, i.e. the
PhotoCORM solution illuminated ex vivo to allow CO to
be released, also enhanced inhibition by GEN and DOX
(Fig. 2a, b, middle) and dramatically potentiated the effect
of CST (Fig. 2c, middle). Even the non-illuminated Photo-
CORM slightly increased growth inhibition by DOX
(Fig. 2b). Thus, the released CO is not the main synergistic
partner of these antibiotics.
Nature of the interactions between antibiotics and
the PhotoCORM
Checkerboard experiments were conducted, in which
increasing concentrations of the title compound were
titrated against increasing concentrations of the antibiotic
(for details see Fig. S1). A combination was considered
to be synergistic when the sum of the fractional inhibi-
tory concentrations (SFIC) was 0.5, non-interacting
when >0.5 and <4, and antagonistic when the SFIC was
4 [35]. These confirmed that activated PhotoCORM
functioned synergistically with antibiotics that target the
cell membrane; for CST (SFIC=0.38) the MIC was
reduced eightfold (from 8 to 1 µgml 1) (Table 1). The
data from the checkerboards and SFIC calculations are
shown in Table S2. Synergy was also seen with the Pho-
toCORM and PMB (SFIC=0.25), where the MIC of
PMB was also reduced eightfold, and with PhotoCORM
and the human cathelicidin peptide LL37 [40]
(SFIC=0.5). Synergy was also seen with antibiotic inhibi-
tors of protein synthesis (Table 1). For DOX, the SFIC
was 0.28 and the activated PhotoCORM reduced the
MIC by fourfold. However, no interaction was found
with the PhotoCORM and TET (SFIC=0.75). OTC was
non-inhibitory and gave no useful MIC. These diverse
interactions of the activated PhotoCORM with members
of the tetracycline family may be explained by the differ-
ent sensitivities of EC958 to these antibiotics. Among the
tetracyclines, DOX had the lowest MIC against EC958
(Table 1), whereas the MICs of TET and OTC were
over twofold higher (>240 µgml 1). Thus, a threshold of
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Fig. 1. Activated PhotoCORM [Mn(CO)3(tpa-k
3N)]Br increases the efficacy of certain antibiotics. Cultures were treated with increasing
concentrations of antibiotics in the absence (.) or presence of 200 µM PhotoCORM (&) in minimal media and illuminated for 6min at
365nm. The antibiotics were: DOX (a); CST (b); KAN (c); GEN (d). OD600nm was recorded after 24 h aerobic incubation at 37

C, 200 r.p.m.
The graphs show the averages ±SEM of three biological repeats. Where error bars appear to be missing, the errors are within the
dimensions of the experimental point.
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susceptibility may be required for synergism to occur. To
test this hypothesis, checkerboard experiments were also
performed with MG1655, an E. coli strain that is
sensitive to both tetracycline and OTC. The PhotoCORM
was synergistic with both these antibiotics against this
strain (Table 1).
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Fig. 2. Combining sub-inhibitory concentrations of antibiotics and [Mn(CO)3(tpa-k
3N)]Br increases growth inhibition. Cultures were
treated with antibiotics alone [GEN, 0.6 µgml 1 (a); DOX, 9 µgml 1 (b); and CST, 1 µgml 1 (c)] or combined with 200µM PhotoCORM
(either illuminated, dark or CO-depleted). Ab, antibiotic; UV, cultures illuminated at 365 nm for 6min. Shown are: cells (no additions),
(.); antibiotic alone (□); PhotoCORM alone (dark, CO-depleted or with UV,&); and a combination of antibiotic and the PhotoCORM (O).
Graphs show the averages ±SEM of three biological repeats.
Table 1. Checkerboard analysis of the synergistic effects of the light-activated PhotoCORM with certain antibiotics
Bacterial strain Antibiotic MICantibiotic* alone (mg ml
 1) MICantibiotic with PhotoCORM (mg ml
 1) S FIC Interaction
EC958 CST 8 1 0.38 Synergy
DOX 100 25 0.28 Synergy
LL37 32 8 0.5 Synergy
OTC >240 >240 No interaction
PMB 2 0.25 0.25 Synergy
TET >240 60 0.75 No interaction
MG1655 OTC 4 0.25 0.31 Synergy
TET 2 0.5 0.31 Synergy
*Minimum inhibitory concentration of antibiotic. Fractional inhibitory concentration. Values are representative of 3 independent biological repeats.
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Antibiotics do not increase accumulation of Mn
from PhotoCORM in EC958 cells
Since CORM-3 is taken up by bacteria [10], we investi-
gated whether the synergistic interactions between [Mn
(CO)3(tpa-k
3N)]Br and CST were due to increased Photo-
CORM (and therefore Mn) uptake in the presence of anti-
biotics. Cultures were treated with UV-activated [Mn
(CO)3(tpa-k
3N)]Br (50 or 150 µM), alone or in combina-
tion with CST (0.5 µgml 1) (Fig. S2). After incubation for
40min, cell pellets, culture supernatants and wash frac-
tions were analysed for Mn content via ICP-MS. No
increased accumulation of Mn was observed when cells
were treated with a combination CST and the Photo-
CORM (Fig. S2). We previously showed that the CORM
does not accumulate measurably in the absence of antibi-
otics [25].
The PhotoCORM contributes to bacterial membrane
damage
We investigated the ability of [Mn(CO)3(tpa-k
3N)]Br
to damage membranes by measuring the release of a fluo-
rescent dye (5(6)-carboxyfluorescein), encapsulated at a
self-quenching concentration (50 µM), from liposomes
composed of 1,2-dioleoyl-sn-glycero-3-phosphoglycerol
(DOPG) with an overall negative charge, or from 1,2-dio-
leoyl-sn-glycero-3-phosphoethanolamine (DOPE)– DOPG
(7 : 3 ratio), which has a more neutral charge (Fig. 3a–d).
In Fig. 3a, PhotoCORM (50 µM) was added to liposomes
at 0.5min (first arrow) and the changes in fluorescence
were recorded. The sample was then illuminated (second
arrow) and further changes in fluorescence were measured.
Increased fluorescence indicated that the PhotoCORM elic-
its dye leakage from liposomes and that the extent of leak-
age increased on illumination. Total membrane damage
was determined by the addition of CST (10 µM) and Tri-
ton X-100 (0.01%), which resulted in maximum leakage
(Fig. 3b, d). The PhotoCORM caused damage to DOPG
(i.e. negatively charged) liposomes, both before and after
illumination, but only damaged the more neutral DOPE–
DOPG liposomes after illumination (Fig. 3c, second
arrow). This suggests that negatively charged DOPG lipo-
somes are more susceptible to damage by the non-acti-
vated PhotoCORM. The membrane charge may be an
important factor since, upon CO loss following photoacti-
vation, the Mn(I) centre is oxidized to Mn(II), possibly
mononuclear, and to dinuclear Mn(III)Mn(III) and Mn
(III)Mn(IV) species [41, 42] while the tpa ligand remains
coordinated to the metal. Liposomes illuminated for 6min
without the PhotoCORM or with PhotoCORM in the
absence of liposomes resulted in no changes in fluores-
cence (data not shown).
To further investigate membrane damage by [Mn(CO)3
(tpa-k3N)]Br, the membrane potential-sensitive dye diSC3
(5) was used to determine the depolarizing effects of the
PhotoCORM on the cytoplasmic membrane of E. coli
EC958. Fluorescence caused by the release of diSC3(5) from
the membrane in response to non-illuminated PhotoCORM
was monitored over a period of 150 s (Fig. 3e). Dose-depen-
dent increases in fluorescence were observed on the addition
of the PhotoCORM up to a concentration of 200 µM. As
described previously [25], the title compound elicits greater
antibacterial activity when illuminated at 365 nm in the
presence of bacterial cells. However, although the optimal
excitation wavelength for diSC3(5) is 660 nm (emission
675 nm), some excitation occurred with our light source at
365 nm, so it was only necessary to photoactivate the
CORM prior to addition of the diSC3(5). Illuminated Photo-
CORM caused some increase in membrane depolarization
at all of the tested concentrations (Fig. 3f), beyond that of
the non-illuminated compound. Together, these results
strongly suggest that the PhotoCORM disrupts membranes,
explaining in part the synergy with other membrane-active
compounds, such as polymyxins and the human
peptide LL37.
The tetracycline resistance gene tetA of EC958 is
down-regulated by PhotoCORM and DOX
The EC958 genome includes pEC958 bearing the tetA gene
[26] that encodes an energy-dependent tetracycline efflux
pump conferring resistance to tetracyclines [43]. As pre-
dicted, tetA was up-regulated in response to DOX (by over
40-fold), in accordance with the resistance of EC958 to
DOX (Table S3). However, when EC958 cells were treated
with a combination of DOX and PhotoCORM, tetA up-reg-
ulation was substantially lower (only 18-fold), suggesting
that the PhotoCORM may impair the efflux of DOX, thus
potentiating its activity.
Evidence for DNA damage by PhotoCORM in
combination with DOX or CST
To seek other damaging effects of [Mn(CO)3(tpa-k
3N)]Br
in combination with CST or DOX we measured the expres-
sion of recA. Bacteria respond to DNA damage by inducing
genes for DNA repair and control of cell division. This
forms part of the SOS response and is regulated by the RecA
protein [44]. Treatment of cells with the PhotoCORM and
CST showed no changes in the expression of recA (not
shown). However, in response to a combination of the Pho-
toCORM and DOX, recA was up-regulated by almost four-
fold (Table S3), whereas neither compound alone
significantly increased transcription (Table S3). Thus,
increased DNA damage from a combination the two com-
pounds may contribute to the observed synergy.
The effects of PhotoCORM and antibiotics on genes
responsive to reactive oxygen species (ROS)
Others have attributed the toxic effects of CORMs on bac-
teria to the generation of ROS [45, 46] but treatments of E.
coli with CORM-3 [10], CO gas [47], the present Photo-
CORM [25] or the manganese carbonyl complex CORM-
401 (L K Wareham and R K Poole, submitted) do not sig-
nificantly up-regulate the expression of genes involved in
the response to ROS. We therefore investigated whether
combining sub-inhibitory concentrations of [Mn(CO)3
(tpa-k3N)]Br with antibiotics altered the expression of
Rana et al., Microbiology
6
genes responsive to ROS. The transcript levels of sodA
(encoding superoxide dismutase) were unaltered following
treatment with PhotoCORM (Table S3), whereas DOX
alone led to a twofold down-regulation of sodA (Table S3).
Notably, when cells were treated with a combination of
PhotoCORM and DOX, sodA was down-regulated fourfold
(Table S3). Other ROS-responsive genes such as ahpC,
which encodes alkyl hydroperoxide reductase, the primary
scavenger of endogenous hydrogen peroxide in E. coli, and
katG, a H2O2-detoxifying catalase, showed no significant
changes in gene expression in response to treatment with
PhotoCORM +/-DOX or CST (data not shown).
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Fig. 3. PhotoCORM perturbs membrane integrity. Membrane damage by [Mn(CO)3(tpa-k
3N)]Br assessed by carboxyfluorescein release
from liposomes prepared from (a), (b) DOPG only or (c), (d) a DOPE–DOPG mix in a 7 : 3 ratio. (a) Liposomes were treated with Photo-
CORM (50 µM) at the first arrow and then illuminated for 6min (second arrow). (b) A control experiment with liposomes but no Photo-
CORM: the first arrow shows the addition of CST (30 µM) and the second arrow shows the addition of 0.01% Triton. Panel (c) is as (a),
except with a 7 : 3 mix of DOPE–DOPG, and (d) is the corresponding no-PhotoCORM control. The excitation wavelength was 495 nm and
emission was at 517 nm. (e), (f) Cytoplasmic membrane depolarization of E. coli EC958 by [Mn(CO)3(tpa-k
3N)]Br measured using the
membrane potential-sensitive dye, diSC3(5). (e) Cells treated with the PhotoCORM without illumination at a range of concentrations. (f)
The PhotoCORM illuminated prior to addition to cells. CST (10 µM) was used as the positive control. The excitation wavelength was
622nm and emission was at 670 nm. The data shown are representative of three technical repeats of two independent experiments.
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Collectively, these data do not support the view that the
PhotoCORM elicits oxidative stress; down-regulation of
sodA and consequential sensitivity to ROS may contribute
to the synergistic effects of DOX and PhotoCORM.
Activated PhotoCORM chelates iron and induces
production of iron-chelating substances by E. coli
EC958
Treatment of EC958 with activated [Mn(CO)3(tpa-k
3N)]Br
results in up-regulation of entE, which encodes an enzyme
involved in enterobactin biosynthesis; exposure of anaerobi-
cally grown E. coli cultures to CO gas also perturbs iron lev-
els [25, 47]. This led us to hypothesize that the title
compound might trigger an iron starvation response in
strain EC958. To establish whether the transcript levels of
iron acquisition genes were reflected in cell physiology, we
performed chrome Azurol S (CAS) assays [39] for
siderophore activity. The CAS dye is blue when bound to Fe
(III) and becomes orange (decreased absorbance at 630 nm)
when the iron reacts with a ligand of higher affinity. Cells
were grown to the late exponential phase (OD600~0.8–1.0),
suspended in Tris-HCl buffer and then treated with the
PhotoCORM or CO-depleted PhotoCORM (both at
300 µM). where appropriate, before illumination. The super-
natants from these samples were then incubated with CAS
assay solution for 1 h at room temperature, and the spectra
were recorded. Culture supernatants from bacteria that were
treated with the PhotoCORM and then illuminated (Fig. 4a,
solid line) showed a significantly lower A630 value compared
to that of the Tris buffer control (P<0.0001, Fig. 4a, dashed
line), whereas the supernatant from control cultures not
treated with the PhotoCORM (Fig. 4a, dot-dashed line) and
the PhotoCORM pre-illuminated in buffer (Fig. 4a, dotted
line) did not change. One explanation for these results is
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Fig. 4. [Mn(CO)3(tpa-k
3N)]Br exacerbates growth inhibition in iron-restricted medium and triggers production of siderophore-like activ-
ity. (a) Culture supernatants were treated either with (solid line) or without (dot-dashed line) the PhotoCORM (300µM) before pre-illumi-
nation at 365 nm for 6min. Additional controls are the PhotoCORM (300 µM) illuminated in Tris-HCl buffer (dotted line) and Tris-HCl
buffer only (dashed line). Samples were treated with CAS assay solution and the absorbance spectra recorded; decreased A630 nm indi-
cates iron loss from CAS due to chelation by the sample. (b)–(d) Culture aliquots were shaken in a 96-well plate and supplemented
with: (b) desferrioxamine; (c) 8-hydroxyquinoline; and (d) citric acid. The graphs show the OD600 at 24 h. Black bars represent no Photo-
CORM and the grey bars represent the addition of activated PhotoCORM (150 µM). The bars are the mean±SEM of three biological
repeats. *, P<0.05; **, P<0.01; ***, P<0.001 (two-way ANOVA).
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that activated PhotoCORM induces the secretion of sidero-
phores or other high-affinity Fe(III) ligands; another is that
activated PhotoCORM, or a subsequent breakdown product
[41, 42], directly chelates iron. [Mn(CO)3(tpa-k
3N)]Br is
unlikely to bind iron because the manganese tricarbonyl
moiety occupies the binding pocket of the tpa co-ligand;
however, upon illumination and CO loss, the manganese–
tpa fragment or the liberated tpa ligand may bind iron.
Alternatively, manganese may displace iron on the dye.
To explore these possibilities, we investigated whether the
free tpa ligand or a simple Mn(II) salt, manganese(II) per-
chlorate, decreased absorbance in the CAS assay. The Mn
(II) salt (300 µM) did not reduce A630, either following illu-
mination or when kept dark (not shown), but high concen-
trations of tpa (1.5mM) in the presence of cells did reduce
A630 compared to that of the supernatant alone (Table 2,
lines 5, 8), although the difference was not significant
(P>0.05). In summary, although cells grown with Photo-
CORM show evidence of iron depletion, the strong iron-
chelating capacity of supernatants from cells treated with
the illuminated PhotoCORM is caused in part by iron chela-
tion by the tpa ligand and also by compounds such as side-
rophores that are produced by EC958 in response to the
activated PhotoCORM. Interestingly, like [Mn(CO)3(tpa-k
3
N)]Br, the tpa ligand caused a larger decrease in absorbance
at 630 nm when added in the presence of cells compared to
when in buffer alone (Table 2, lines 5 and 9; P<0.05), sug-
gesting that tpa is also able to trigger the production of
iron-chelating substances in cultures of EC958. Only a slight
decrease in A630 was observed for cultures treated with
higher concentrations of the PhotoCORM (1.5mM) in Tris
buffer kept in the dark (data not shown), providing further
evidence that the intact PhotoCORM does not chelate iron.
Iron chelation exacerbates the antimicrobial effects
of PhotoCORM, while iron supplementation reduces
antimicrobial activity
The ability of [Mn(CO)3(tpa-k
3N)]Br to trigger an iron star-
vation response suggested that iron chelators would exacer-
bate the antimicrobial activity of activated PhotoCORM.
Bacteria were therefore grown with chelators with different
stability constants for Fe(II) and Fe(III): desferrioxamine
[log stability Fe(III)=30.6], citric acid [log stability Fe(II)
=4.4 and Fe(III)=11.4], or 8-hydroxyquinoline [log stability
Fe(II)=15 and Fe(III)=26.3] [48, 49]. While treatment of
cells with the activated PhotoCORM alone (150 µM) did not
cause significant reductions in cell growth compared to
untreated cells (Fig. 4b–d), growth (OD at 600 nm) was sig-
nificantly inhibited when it was combined with increasing
concentrations of desferrioxamine (Fig. 4b), 8-hydroxyqui-
noline (Fig. 4c) or citric acid (Fig. 4d) (P0.001). To test
the effect of the converse treatment, i.e. provision of addi-
tional iron, EC958 cultures were grown in either normal or
Fe-supplemented media (10-fold or 50-fold increases in the
basal Fe concentration of 31 µM) in the presence or absence
of the activated [Mn(CO)3(tpa-k
3N)]Br (250 µM). Iron sup-
plementation of the medium reduced the antimicrobial
activity of the PhotoCORM (Fig. S3). Having shown that
iron starvation is a major player in the antimicrobial activity
of [Mn(CO)3(tpa-k
3N)]Br, we used ICP-MS to measure the
intracellular iron levels in EC958 cells treated for 30min
with the activated PhotoCORM at a concentration causing
substantial inhibition of growth [25] (300 µM); the intracel-
lular iron levels were 60% lower following treatment with
the PhotoCORM compared to untreated cells (183 and
459 µM respectively), confirming the ability of the title com-
pound to deplete intracellular iron.
The role of iron in the combined antimicrobial
activity of DOX and PhotoCORM
The suppression of bacterial growth by tetracyclines may in
part be caused by iron limitation [50, 51], while high iron
levels block the accumulation of tetracyclines [52]. Tetracy-
clines chelate iron and lower DOX concentrations are
required to inhibit bacterial growth in low-iron environ-
ments [53]. We therefore investigated whether a combina-
tion of DOX and [Mn(CO)3(tpa-k
3N)]Br exacerbated iron
chelation (Table 2). The addition of DOX (96 µgml 1) to
buffer significantly reduced the A630 of CAS compared with
buffer alone (P<0.005), but a lower DOX concentration did
not (Table 2, lines 4, 10). Interestingly, the addition of DOX
to a culture elicited a greater reduction in A630 than
its addition to buffer (P<0.05), although this difference was
not significant at the lower concentration of DOX used
(Table 2, lines 3 and 7). Thus, metal chelation by high con-
centrations of DOX may also cause the secretion of iron-
Table 2. Iron chelation assays
Data are listed in order of decreasing iron-chelating activity (increas-
ing A630). Samples of PhotoCORM (+=300 µM), DOX (+=9µgml
 1, +
+=96 µgml 1), or the ligand tpa (+=300 µM, ++=1.5mM) were added to
either Tris-HCl buffer, 50mM, pH 7.4, or to a suspension of EC958 in
the same buffer. ’–’ indicates that this compound/conditionwas not
present in this sample. Samples were kept in the dark unless stated,
in which case they were illuminated in situ at 365 nm for 6min. Sam-
ples containing bacteria were then centrifuged (4000 r.p.m.) and 500 µl
supernatant was incubated at room temperature for 1 h with 500 µl
CAS dye. A UV visible spectrum was then recorded for each sample
(300–800 nm). The mean A630 value for each sample is shown here ±SD
(n=3).
PhotoCORM tpa DOX
Light in
situ
EC958
cells A630
1 +     + + 0.08±0.011
2 +   + + + 0.17±0.11
3     ++   + 0.30±0.02
4     ++     0.35±0.07
5   ++     + 0.42±0.07
6   +     + 0.55±0.03
7     +   + 0.56±0.02
8         + 0.58±0.11
9   ++       0.59±0.03
10     +     0.63±0.03
11 +         0.65±0.06
12   +       0.71±0.04
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chelating substances such as siderophores by strain EC958.
When added to a bacterial cell suspension, the combination
of DOX (9 µgml 1) with activated PhotoCORM (300 µM)
caused a greater decrease in A630 than DOX alone (Table 2,
lines 2 and 7; P<0.05), but not compared to activated Photo-
CORM alone (Table 2, line 1). Thus activated PhotoCORM
in the presence of bacterial cells is sufficient to cause the
maximum decrease in A630, and so is at the outer sensitivity
limits of this assay. We conclude that [Mn(CO)3(tpa-k
3N)]
Br, or rather its solution products, and DOX each inhibit
bacterial growth by chelating iron, explaining in part why
these compounds act synergistically.
The effect of Fe(III) supplementation on the synergistic
effects of activated PhotoCORM and DOX was studied in
bacterial cultures (Fig. 5). EC958 cells were grown in either
minimal medium or medium supplemented with either a
10- or 50-fold excess of iron. Cells were treated with DOX
(24 µgml 1) and PhotoCORM (200 µM), which, in medium
without Fe supplementation caused a prolonged and com-
plete growth inhibition (Fig. 5a). However, in medium sup-
plemented with 10-fold more Fe, sustained growth
inhibition was not observed (Fig. 5b). This reversal of
inhibition was more pronounced when 50-fold excess Fe
was included in the medium (Fig. 5c). Cells started to
recover at 14 h, reaching a similar OD600 to that of
untreated cells at 24 h. Fig. 5d shows little difference in the
growth of EC958 in minimal media with or without iron
supplementation. Thus, iron chelation is critical in the
observed synergy between the two antimicrobials.
CO gas does not elicit iron-chelating activity and is
unable to potentiate the antimicrobial activity of
DOX in EC958
CO gas triggers an iron starvation response in anaerobic E.
coli MG1655 cells, leading to the up-regulation of numerous
iron acquisition genes and siderophore-like activity [47].
Since [Mn(CO)3(tpa-k
3N)]Br releases two CO groups per
molecule upon illumination, we investigated the role of CO
in siderophore production in aerobically grown EC958. The
CAS assay was repeated, but cells were bubbled with CO gas
(5min) alone (A630=0.71±0.04) or in the presence of
300 µM tpa and Mn(ClO4)2 (A630=0.57±0.02), and the
supernatant from these cultures was added to the CAS
reagent. There was no significant difference (P>0.05) in
A630 between samples treated with CO and the samples
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Fig. 5. Iron supplementation reverses the combined toxicity of DOX and light-activated [Mn(CO)3(tpa-k
3N)]Br. Cells were grown in DMM
(a), or media supplemented with 10-fold (b) or 50-fold (c) excesses of Fe(III). In (a), (b) and (c) are shown: cells in media alone (O),
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without CO treatment (A630=0.67±0.02), suggesting that
CO does not contribute to the production of iron-chelating
molecules in response to [Mn(CO)3(tpa-k
3N)]Br. When
strain EC958 was treated with increasing concentrations of
DOX (12–96 µgml 1) and CO-saturated solution (400 µM),
CO did not potentiate the antimicrobial activity of DOX
(data not shown). The MIC of DOX with or without CO
remained at 96 µgml 1.
DISCUSSION
Bacterial infections endanger human health worldwide, a
threat that is compounded by the relentless spread of anti-
microbial resistance (AMR) and the slow development of
new antibiotics. Observers claim that we are approaching
the ‘post-antibiotic era’ [54]. Indeed, in 2015 researchers
identified bacteria resistant to CST (the ‘drug of last resort’)
in patients and livestock in China [55]. To meet these chal-
lenges, numerous international initiatives on AMR have
been launched, including a World Health Organisation
(WHO) global action plan. The spectre of global antibiotic
resistance demands: (1) an accelerated search for new anti-
biotics via private/public partnerships; (2) better under-
standing of how non-antibiotic antimicrobial agents act and
can therefore be used synergistically with established antibi-
otics [56]; (3) a search for new antimicrobials with distinct
modes of action (e.g. CORMs) [16]; and (4) deeper under-
standing of how the innate immunity system can be used to
aid clearing of bacterial infections.
The WHO recently announced a global priority list of anti-
biotic-resistant bacteria and identified antibiotic-resistant
bacteria of the Enterobacteriaceae, including E. coli, as being
amongst the most critical [57]. Therefore the search for
novel treatment strategies is especially important for multi-
drug resistant strains such as EC958 [26]. We had already
briefly described the ability of [Mn(CO)3(tpa-k
3N)]Br to
potentiate the antimicrobial effect of DOX [25], but the cur-
rent work is the first comprehensive study of synergy
between a range of antibiotics and a PhotoCORM. We show
that [Mn(CO)3(tpa-k
3N)]Br potentiates the antibacterial
activity of tetracycline and polymyxin antibiotics. Multifac-
torial effects are evident. First, the PhotoCORM disrupts
membranes, leading to the reduced MIC of the combined
treatments. The cationic polypeptides CST and PMB inter-
act with anionic lipopolysaccharide (LPS) molecules in the
outer membrane of Gram-negative bacteria and displace
calcium and magnesium ions, thus disrupting the cell mem-
brane [58, 59]. Although the observed synergies may there-
fore result from increased entry of the PhotoCORM into
bacteria and enhanced access to intracellular targets, we
found no increased intracellular accumulation of Mn (and
thus the PhotoCORM) in the presence of antibiotics (Fig.
S2). Second, the PhotoCORM or, more likely, the products
of photoactivation, but not CO, bind iron and trigger an
iron starvation response in strain EC958, including the pro-
duction of siderophore-like activity. The observed synergy
may reflect the iron-chelating activity of both the Photo-
CORM and tetracyclines. Tetracyclines chelate iron [51–53]
and antibiotics such as DOX and MIN are more effective in
iron-restricted environments. The antimicrobial action of
tetracyclines against Plasmodium falciparum infections is
inhibited by iron and a catechol inhibitor, FR160, potenti-
ates the activity of DOX [60]. Bacteria colonizing the uri-
nary tract face extremely low iron availability; consequently,
UPEC strains such as EC958 express a wide variety of iron
acquisition systems, such as siderophore production, in
order to survive inside the host [61]. Finally, reduced
expression of the tetA gene encoding a tetracycline efflux
pump may contribute to the synergy observed.
Although CO-releasing molecules (CORMs) have been her-
alded as promising and novel antimicrobial agents, there
has been uncertainty about their mode(s) of action. How-
ever, the present results clearly demonstrate a lack of signifi-
cant CO-mediated effects in the case of [Mn(CO)3(tpa-k
3
N)]Br. CO-depleted PhotoCORM was able to potentiate the
activity of CST to the same extent as the activated Photo-
CORM. Similarly, cells treated with the non-illuminated
PhotoCORM, i.e. with all CO ligands still attached, also
showed some potentiation of DOX against EC958 cells.
Cells treated with CO gas and DOX, on the other hand,
showed no combined effect. These findings are in agree-
ment with the study by Wareham et al. [47], which showed
that, in contrast to the protective effects of other gasotrans-
mitters such as NO and H2S [62, 63], CO gas had no effects,
neither protection nor potentiation, against several classes
of antibiotics [47]. This suggests a ‘Janus-headed’ activity of
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Fig. 6. The ‘Janus-headed’ activity of [Mn(CO)3(tpa-k
3N)]Br. The title compound has multi-faceted properties, in which either the Mn
(CO)3 moiety acts as a photolabile protective group for the tpa ligand (left) or the Mn(tpa) fragment acts as a carrier for carbon monox-
ide (right).
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the title compound, where the Mn(tpa) fragment may act as
a carrier for up to three CO ligands (with subsequent CO
binding to terminal oxidases and respiratory inhibition [20,
25]), whereas the carbonyl ligands also act as photolabile
‘protective groups’, which prevent the biological activity of
the Mn(tpa) fragment while coordinated (Fig. 6).
Nevertheless, CORMs have shown promise in combination
therapy in a number of bacterial species. Sub-lethal doses of
CORM-2 were combined with metronidazole, amoxicillin
or clarithromycin and were found to potentiate antibiotic
effects on clinical isolates of H. pylori [64]. Similarly,
CORM-2 was found to act as an adjuvant to tobramycin
against P. aeruginosa biofilms [65]. CORM-2 potentiates
the effects of DOX, CTX and TMP [47]. This study shows
for the first time that the PhotoCORM [Mn(CO)3(tpa-k
3
N)]Br potentiates the activities of several antibiotics, and
suggests future strategies to enhance antimicrobial activity
against such multi-drug-resistant pathogens.
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